Cargando…

Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer’s disease and related dementias?

This scientific commentary refers to ‘No association between initiation of phosphodiesterase-5 inhibitors and risk of incident Alzheimer’s disease and related dementia: results from the Drug Repurposing for Effective Alzheimer’s Medicines (DREAM) study’ by Desai et al. (https://doi.org/10.1093/brain...

Descripción completa

Detalles Bibliográficos
Autor principal:	Newby, Danielle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Scientific Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598549/ https://www.ncbi.nlm.nih.gov/pubmed/36324868 http://dx.doi.org/10.1093/braincomms/fcac260

Ejemplares similares

Alzheimer’s disease, cerebrovascular disease and dementia: lump, split or integrate?
por: Biessels, Geert Jan
Publicado: (2022)

Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis
por: Ahidjo, Bintou Ahmadou, et al.
Publicado: (2016)

An anti-amyloid therapy works for Alzheimer’s disease: why has it taken so long and what is next?
por: Hardy, John, et al.
Publicado: (2023)

Music, memory and mechanisms in Alzheimer’s disease
por: Clark, Camilla N., et al.
Publicado: (2015)

Concatenating plasma p-tau to Alzheimer’s disease
por: Tijms, Betty M, et al.
Publicado: (2021)

In the blood: biomarkers for amyloid pathology and neurodegeneration in Alzheimer’s disease
por: Toombs, Jamie, et al.
Publicado: (2020)

Detecting early changes in Alzheimer’s disease with graph theory
por: Pereira, Joana B
Publicado: (2020)

Metabolic effects of phosphodiesterase III inhibitors: another reason to promote their use?
por: Simkova, Vladislava, et al.
Publicado: (2007)

Preclinical Alzheimer’s disease: how to predict who will decline next year?
por: Hanseeuw, Bernard J, et al.
Publicado: (2023)

Is phosphorylated tau a good biomarker of synapse pathology in Alzheimer’s disease?
por: Saura, Carlos A, et al.
Publicado: (2023)

Importance of national plans for Alzheimer’s disease and dementia
por: Wortmann, Marc
Publicado: (2013)

Compellingly negative: Bayesian analysis shows handedness and dementia are not associated
por: McManus, I C
Publicado: (2023)

Alzheimer, dementia and the living will: a proposal
por: Burlá, Claudia, et al.
Publicado: (2014)

AB030. Evolution of phosphodiesterase type 5 inhibitors
por: Moon, Du Geon
Publicado: (2016)

COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2020)

Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?
por: Mondaini, Nicola
Publicado: (2020)

Evolution of Phosphodiesterase-5 Inhibitors
por: Moon, Du Geon
Publicado: (2015)

Plasma p-tau217: from ‘new kid’ to most promising candidate for Alzheimer’s disease blood test
por: Teunissen, Charlotte E, et al.
Publicado: (2020)

Examination of a non-invasive biomarker for the diagnosis of prodromal Alzheimer's disease and Alzheimer's disease Dementia
por: Dupree, Emmalyn J., et al.
Publicado: (2020)

A toxic subset of soluble α-synuclein species in dementia with Lewy body
por: Castillo-Carranza, Diana L
Publicado: (2020)

Reconciling profiles of reward-seeking versus reward-restricted behaviours in frontotemporal dementia
por: Horne, Kristina, et al.
Publicado: (2023)

Transfixed by transgenics: how pathology assumptions are slowing progress in Alzheimer's disease and related dementia research
por: D'Adamio, Luciano
Publicado: (2023)

Defining and describing the pre-dementia stages of familial Alzheimer's disease
por: Ryan, Natalie S, et al.
Publicado: (2011)

Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements
por: Gheorghiu, Oana Ramona Cătălina, et al.
Publicado: (2023)

Phosphodiesterase type 5 inhibitors: Irrational use in Saudi Arabia
por: Alshahrani, Saad, et al.
Publicado: (2016)

Phosphodiesterase Type 5 Inhibitors and sudden sensorineural hearing loss
por: Barreto, Monique Antunes de Souza Chelminski, et al.
Publicado: (2015)

Unraveling the potential co-contributions of cerebral small vessel vasculopathy to the pathogenesis of Alzheimer’s dementia
por: Edwards, Jodi D., et al.
Publicado: (2015)

Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants
por: Tiwari, Amit K., et al.
Publicado: (2013)

Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions
por: Kang, Byung Woo, et al.
Publicado: (2022)

Cyclic nucleotide phosphodiesterase 1 and vascular aging
por: Yan, Chen
Publicado: (2015)

Combination phosphodiesterase type 4 inhibitor and phosphodiesterase type 5 inhibitor treatment reduces non-voiding contraction in a rat model of overactive bladder
por: Balog, Brian M., et al.
Publicado: (2019)

Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review
por: Wang, Jie, et al.
Publicado: (2017)

Immune checkpoint inhibitor induced neurocognitive deficits in patients
por: Zeiser, Robert, et al.
Publicado: (2023)

Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors
por: Al-Ameri, H, et al.
Publicado: (2009)

Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks
por: Jackson, G, et al.
Publicado: (2010)

Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
por: Sung, Hyun Hwan, et al.
Publicado: (2012)

Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications
por: Corinaldesi, C., et al.
Publicado: (2015)

Revisiting the halogen bonding between phosphodiesterase type 5 and its inhibitors
por: Jedwabny, Wiktoria, et al.
Publicado: (2019)

Modelling Charcot-Marie-Tooth disease in a dish reveals common cell type-specific alterations
por: Müller, Juliane S, et al.
Publicado: (2021)

Home-Based Care for People with Alzheimer’s Disease and Related Dementias (ADRD) during COVID-19 Pandemic: From Challenges to Solutions
por: sm-Rahman, Atiqur, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0rp2q4jchcihh3lgm2eistbkji